Christopher R. Reidy - 15 Oct 2026 Form 4 Insider Report for Encompass Health Corp (EHC)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
19 Oct 2026, 15:42:19 UTC
Prior SEC filing
16 Jul 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Patrick Darby, attorney-in-fact for Christopher R. Reidy
Filing notes and source

Key filing fact

Christopher R. Reidy filed Form 4 for Encompass Health Corp (EHC) on 19 Oct 2026.

Key facts

  • This page summarizes Christopher R. Reidy's Form 4 filing for Encompass Health Corp (EHC).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 19 Oct 2026, 15:42.

Change

  • Previous filing in this sequence was filed on 16 Jul 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001290907 Primary reporting owner

Reidy Christopher R

Relationship
Director
Address
9001 LIBERTY PARKWAY, BIRMINGHAM
Signature
/s/ Patrick Darby, attorney-in-fact for Christopher R. Reidy
Signature date
19 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EHC transaction

Encompass Health Common Stock

Award

Transaction value
Shares
+20
Change %
+0.11%
Price
$0.000000*
Shares after
17,797
Date
15 Oct 2026
Ownership
Direct
Footnotes
F1
EHC transaction

Encompass Health Common Stock

Award

Transaction value
Shares
+284
Change %
+1.6%
Price
$126.89*
Shares after
18,081
Date
19 Oct 2026
Ownership
Direct
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2026, Encompass Health paid a dividend on its common stock of $0.21 per share and the closing price was $127.77. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.

Footnote F2

The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.21 per share paid on October 15, 2026.

Footnote F3

This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $126.83 to $126.89, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .